TABLE OF CONTENTS
Volume 21, Issue 1 (January 2007)
Editorials
ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia
P Ghia, K Stamatopoulos, C Belessi, C Moreno, S Stilgenbauer, F Stevenson, F Davi and R Rosenquist on behalf of the European Research Initiative on CLL (ERIC)
Leukemia 21: 1-3; doi:10.1038/sj.leu.2404457
Flow cytometry analysis of acute promyelocytic leukemia: the power of 'surface hematology'
R Di Noto, P Mirabelli and L Del Vecchio
Leukemia 21: 4-8; doi:10.1038/sj.leu.2404412
An internationally recognized uniform cytogenetic classification system is needed for multiple myeloma
A Dispenzieri
Leukemia 21: 9-11; doi:10.1038/sj.leu.2404450
Leading Article
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus
P Dreger, P Corradini, E Kimby, M Michallet, D Milligan, J Schetelig, W Wiktor-Jedrzejczak, D Niederwieser, M Hallek and E Montserrat on behalf of the Chronic Leukemia Working Party of the EBMT
Leukemia 21: 12-17; advance online publication, November 16, 2006; doi:10.1038/sj.leu.2404441
Reviews
Molecular pathways in follicular lymphoma
R J Bende, L A Smit and C J M van Noesel
Leukemia 21: 18-29; advance online publication, October 12, 2006; doi:10.1038/sj.leu.2404426
Proteasome inhibitors: antitumor effects and beyond
A Nencioni, F Grünebach, F Patrone, A Ballestrero and P Brossart
Leukemia 21: 30-36; advance online publication, November 9, 2006; doi:10.1038/sj.leu.2404444
Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities
P De Paepe and C De Wolf-Peeters
Leukemia 21: 37-43; advance online publication, October 12, 2006; doi:10.1038/sj.leu.2404449
The history of the angiogenic switch concept
D Ribatti, B Nico, E Crivellato, A M Roccaro and A Vacca
Leukemia 21: 44-52; advance online publication, September 21, 2006; doi:10.1038/sj.leu.2404402
Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia
D E Spaner and A Masellis
Leukemia 21: 53-60; advance online publication, October 26, 2006; doi:10.1038/sj.leu.2404456
Concise Review
Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?
T C Karagiannis and A El-Osta
Leukemia 21: 61-65; advance online publication, November 16, 2006; doi:10.1038/sj.leu.2404464
Original Articles
Acute Leukemias
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group
A-L Taksin, O Legrand, E Raffoux, T de Revel, X Thomas, N Contentin, R Bouabdallah, C Pautas, P Turlure, O Reman, C Gardin, B Varet, S de Botton, F Pousset, H Farhat, S Chevret, H Dombret and S Castaigne
Leukemia 21: 66-71; advance online publication, October 19, 2006; doi:10.1038/sj.leu.2404434
A novel Leu153Ser mutation of the Fanconi anemia FANCD2 gene is associated with severe chemotherapy toxicity in a pediatric T-cell acute lymphoblastic leukemia
A Borriello, A Locasciulli, A M Bianco, M Criscuolo, V Conti, P Grammatico, S Cappellacci, A Zatterale, F Morgese, V Cucciolla, D Delia, F Della Ragione and A Savoia
Leukemia 21: 72-78; advance online publication, November 9, 2006; doi:10.1038/sj.leu.2404468
Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features
M Breccia, G Avvisati, R Latagliata, I Carmosino, A Guarini, M S De Propris, F Gentilini, M C Petti, G Cimino, F Mandelli and F Lo-Coco
Leukemia 21: 79-83; advance online publication, August 24, 2006; doi:10.1038/sj.leu.2404377
Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells
M Kraus, T Rückrich, M Reich, J Gogel, A Beck, W Kammer, C R Berkers, D Burg, H Overkleeft, H Ovaa and C Driessen
Leukemia 21: 84-92; advance online publication, October 5, 2006; doi:10.1038/sj.leu.2404414
Chronic Myeloproliferative Disorders
Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia
M Pocaly, V Lagarde, G Etienne, J-A Ribeil, S Claverol, M Bonneu, F Moreau-Gaudry, V Guyonnet-Duperat, O Hermine, J V Melo, M Dupouy, B Turcq, F-X Mahon and J-M Pasquet
Leukemia 21: 93-101; advance online publication, November 16, 2006; doi:10.1038/sj.leu.2404463
Chronic Lymphocytic Leukemia
ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor
R Zanotti, A Ambrosetti, M Lestani, P Ghia, C Pattaro, A Remo, F Zanetti, S Stella, O Perbellini, G Prato, G Guida, F Caligaris-Cappio, F Menestrina, G Pizzolo and M Chilosi
Leukemia 21: 102-109; advance online publication, November 2, 2006; doi:10.1038/sj.leu.2404458
The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease
P G Longo, L Laurenti, S Gobessi, A Petlickovski, M Pelosi, P Chiusolo, S Sica, G Leone and D G Efremov
Leukemia 21: 110-120; advance online publication, October 5, 2006; doi:10.1038/sj.leu.2404417
Cytogenetics and Molecular Genetics
Clinical, cytogenetic and molecular characteristics of 14 T-ALL patients carrying the TCR
-HOXA rearrangement: a study of the Groupe Francophone de Cytogénétique Hématologique
B Cauwelier, H Cavé, C Gervais, M Lessard, C Barin, C Perot, J Van den Akker, F Mugneret, C Charrin, M P Pagès, M-J Grégoire, P Jonveaux, M Lafage-Pochitaloff, M J Mozzicconacci, C Terré, I Luquet, P Cornillet-Lefebvre, B Laurence, G Plessis, C Lefebvre, D Leroux, H Antoine-Poirel, C Graux, L Mauvieux, P Heimann, C Chalas, E Clappier, B Verhasselt, Y Benoit, B D Moerloose, B Poppe, N Van Roy, K D Keersmaecker, J Cools, F Sigaux, J Soulier, A Hagemeijer, A D Paepe, N Dastugue, R Berger and F Speleman
Leukemia 21: 121-128; advance online publication, October 12, 2006; doi:10.1038/sj.leu.2404410
Stem Cells
HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia
A-L Herr, M Labopin, D Blaise, N Milpied, M Potter, M Michallet, W Heit, F Ferrara, J Esteve, W Arcese, G Ehninger, J M Rowe, G Kobbe, A Rosselet, D Bunjes, B Rio, M Brune, A Nagler, N C Gorin, F Frassoni and V Rocha on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Leukemia 21: 129-135; advance online publication, November 23, 2006; doi:10.1038/sj.leu.2404461
Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice
M Ninomiya, A Abe, A Katsumi, J Xu, M Ito, F Arai, T Suda, M Ito, H Kiyoi, T Kinoshita and T Naoe
Leukemia 21: 136-142; advance online publication, October 12, 2006; doi:10.1038/sj.leu.2404432
Myeloma
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis
N C Gutiérrez, M V Castellanos, M L Martín, M V Mateos, J M Hernández, M Fernández, D Carrera, L Rosiñol, J M Ribera, J M Ojanguren, L Palomera, S Gardella, L Escoda, J C Hernández-Boluda, J L Bello, J de la Rubia, J J Lahuerta and J F San Miguel on behalf of GEM/PETHEMA Spanish Group
Leukemia 21: 143-150; advance online publication, October 5, 2006; doi:10.1038/sj.leu.2404413
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials
S Jagannath, P G Richardson, P Sonneveld, M W Schuster, D Irwin, E A Stadtmauer, T Facon, J-L Harousseau, J M Cowan and K C Anderson
Leukemia 21: 151-157; advance online publication, November 9, 2006; doi:10.1038/sj.leu.2404442
Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma
B Arnulf, S Lecourt, J Soulier, B Ternaux, M-Noelle Lacassagne, A Crinquette, J Dessoly, A-K Sciaini, M Benbunan, C Chomienne, J-P Fermand, J-P Marolleau and J Larghero
Leukemia 21: 158-163; advance online publication, November 9, 2006; doi:10.1038/sj.leu.2404466
Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion
V Sagaster, H Ludwig, H Kaufmann, V Odelga, N Zojer, J Ackermann, E Küenburg, R Wieser, C Zielinski and J Drach
Leukemia 21: 164-168; advance online publication, November 9, 2006; doi:10.1038/sj.leu.2404459
Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma
T Ise, S Nagata, R J Kreitman, W H Wilson, A S Wayne, M Stetler-Stevenson, M R Bishop, D A Scheinberg, L Rassenti, T J Kipps, R A Kyle, D F Jelinek and I Pastan
Leukemia 21: 169-174; advance online publication, October 19, 2006; doi:10.1038/sj.leu.2404445
Letters to the Editor
Enhanced CD28 signaling may be a common mechanism underlying resistance to regulation
E A Wohlfert and R B Clark
Leukemia 21: 175; advance online publication, November 16, 2006; doi:10.1038/sj.leu.2404453
Reply to 'Enhanced CD28 signaling may be a common mechanism underlying resistance to regulation' by E Wohlfert and Clark RB
A Loskog and M K Brenner
Leukemia 21: 175; advance online publication, November 16, 2006; doi:10.1038/sj.leu.2404454
Association of folate transporter SLC19A1 polymorphisms with the outcome of multiple myeloma after chemotherapy and tandem autologous transplantation
V Maggini, G Buda, S Galimberti, E Conidi, N Giuliani, F Morabito, G Genestreti, P Iacopino, V Rizzoli, R Barale, M Petrini and A M Rossi
Leukemia 21: 176-178; advance online publication, October 26, 2006; doi:10.1038/sj.leu.2404455
Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2
S Mishra, V Pertz, B Zhang, P Kaur, H Shimada, J Groffen, Z Kazimierczuk, L A Pinna and N Heisterkamp
Leukemia 21: 178-180; advance online publication, November 2, 2006; doi:10.1038/sj.leu.2404460
Silencing L-selectin expression by siRNA attenuated metastasis of murine lymphoid neoplasm cell P388D1 to peripheral lymph nodes
Y Zuo, W Wei, C Liu, L Zhao, L Wang and J Zhang
Leukemia 21: 180-183; advance online publication, November 9, 2006; doi:10.1038/sj.leu.2404469
JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML
S Schnittger, U Bacher, W Kern, C Haferlach and T Haferlach
Leukemia 21: 183-184; advance online publication, November 9, 2006; doi:10.1038/sj.leu.2404465
Predictive value of p16 or Rb inactivation in a model of naturally occurring canine non-Hodgkin's lymphoma
J F Modiano, M Breen, V E O Valli, J W Wojcieszyn and G R Cutter
Leukemia 21: 184-187; advance online publication, September 21, 2006; doi:10.1038/sj.leu.2404392
PPAR
-mediated growth suppression of baicalein and dexamethasone in human myeloma cells
K-I Otsuyama, Z Ma, S Abroun, J Amin, K Shamsasenjan, H Asaoku and M M Kawano
Leukemia 21: 187-190; advance online publication, November 2, 2006; doi:10.1038/sj.leu.2404462
Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy
K Tokita, K Maki, J Tadokoro, Y Nakamura, Y Arai, K Sasaki, M Eguchi-Ishimae, M Eguchi and K Mitani
Leukemia 21: 190-192; advance online publication, November 23, 2006; doi:10.1038/sj.leu.2404397
